TheStreet upgraded shares of Haemonetics Co. (NYSE:HAE) from a c rating to a b- rating in a research report report published on Thursday, April 13th.
Several other research firms also recently commented on HAE. Zacks Investment Research downgraded Haemonetics from a hold rating to a strong sell rating in a research note on Tuesday, April 4th. Barrington Research downgraded Haemonetics from an outperform rating to a market perform rating in a research note on Tuesday, February 7th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Haemonetics presently has an average rating of Hold and an average price target of $35.83.
Shares of Haemonetics (NYSE:HAE) opened at 40.30 on Thursday. The company has a 50-day moving average price of $41.42 and a 200 day moving average price of $39.59. The firm’s market capitalization is $2.10 billion. Haemonetics has a 12-month low of $27.42 and a 12-month high of $43.62.
Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Monday, May 8th. The medical instruments supplier reported $0.39 EPS for the quarter, beating the consensus estimate of $0.37 by $0.02. Haemonetics had a return on equity of 10.51% and a net margin of 1.79%. The business had revenue of $228.10 million for the quarter, compared to the consensus estimate of $215.06 million. During the same quarter in the prior year, the business earned $0.37 earnings per share. Haemonetics’s revenue for the quarter was down 5.9% on a year-over-year basis. Equities research analysts expect that Haemonetics will post $1.60 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Haemonetics by 48,854.9% in the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after buying an additional 6,276,880 shares during the period. Wellington Management Group LLP increased its stake in shares of Haemonetics by 22.6% in the first quarter. Wellington Management Group LLP now owns 4,192,350 shares of the medical instruments supplier’s stock worth $170,084,000 after buying an additional 774,089 shares during the period. Columbia Wanger Asset Management LLC acquired a new stake in shares of Haemonetics during the first quarter worth about $23,786,000. American Capital Management Inc. acquired a new stake in shares of Haemonetics during the third quarter worth about $20,732,000. Finally, Norges Bank acquired a new stake in shares of Haemonetics during the fourth quarter worth about $20,512,000. Institutional investors own 99.43% of the company’s stock.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
What are top analysts saying about Haemonetics Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Haemonetics Co. and related companies.